Cargando…

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784272/ https://www.ncbi.nlm.nih.gov/pubmed/33397455 http://dx.doi.org/10.1186/s40164-020-00186-y

Ejemplares similares

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
por: Rabinovich, Emma, et al.
Publicado: (2021)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort
por: Shapiro, Lauren C, et al.
Publicado: (2021)

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
por: Abbasi, Ahmed, et al.
Publicado: (2020)

Autologous stem cell transplantation in an older adult population
por: Fedorov, Kateryna, et al.
Publicado: (2022)

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
por: Rahmani, Nora E., et al.
Publicado: (2021)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

Primary central nervous system lymphoma: treatment access and outcomes in HIV positive patients in a minority rich cohort
por: Narvel, Hiba, et al.
Publicado: (2023)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients
por: D'Aiello, Angelica, et al.
Publicado: (2020)

IL1RAP potentiates multiple oncogenic signaling pathways in AML
por: Mitchell, Kelly, et al.
Publicado: (2018)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
por: D'Aiello, Angelica, et al.
Publicado: (2022)

Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
por: Bazarbachi, Abdul-Hamid, et al.
Publicado: (2023)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
por: Solomon, Scott R., et al.
Publicado: (2023)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
por: Rahimi, Muhammad Naim Bin Che, et al.
Publicado: (2023)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
por: Annamaraju, Pavan, et al.
Publicado: (2020)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
por: Alrajhi, Abdullah M., et al.
Publicado: (2019)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Nagate, Yasuhiro, et al.
Publicado: (2023)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure
por: Shah, Urvi A., et al.
Publicado: (2018)

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t90q2cd7vjo8i0m25n0vneha2n